Causes and determinants of mortality in HIV-infected adults with tuberculosis: An analysis from the CAMELIA ANRS 1295-CIPRA KH001 randomized trial

Clinical Infectious Diseases

Volumn 59, Issue 3, 2014, Pages 435-445

  Marcy, Olivier ^a   Laureillard, Didier ^a,b   Madec, Yoann ^c   Chan, Sarin ^a,d   Mayaud, Charles ^e   Borand, Laurence ^a   Prak, Narom ^f   Kim, Chindamony ^g,h   Lak, Kim Khemarin ^a,i   Hak, Chanroeurn ^d   Dim, Bunnet ^a,h,j   Sok, Thim ^a   Delfraissy, Jean François ^k   Goldfeld, Anne E ^a,l   Blanc, François Xavier ^m  

^a INSTITUT PASTEUR DU CAMBODGE   (Cambodia)

^b Epidemiology and Public Health Unit Institut Pasteur du Cambodge ^*  (Viet Nam)

^c INSTITUT PASTEUR   (France)

^d Calmette Hospital   (Cambodia)

^e HÔPITAL TENON   (France)

^f Khmer Soviet Friendship Hospital   (Cambodia)

^g Donkeo Provincial Hospital   (Japan)

^h MÉDECINS SANS FRONTIÈRES   (Switzerland)

ⁱ Svay Rieng Provincial Hospital   (Cambodia)

^j Siem Reap Provincial Hospital   (Cambodia)

^k BICÊTRE HOSPITAL   (France)

^l BOSTON CHILDREN S HOSPITAL   (United States)

^m CHU de Nantes   (France)

more..

Author keywords

Adult; Cause of death; HIV; Mortality; Tuberculosis

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIINFECTIVE AGENT; COTRIMOXAZOLE; TUBERCULOSTATIC AGENT;

ADULT; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; COMPLICATION; CONTROLLED STUDY; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; HUMAN; IMMUNOCOMPROMISED PATIENT; MALE; MORTALITY; RANDOMIZED CONTROLLED TRIAL; TUBERCULOSIS;

ADULT; ANTI-HIV AGENTS; ANTI-INFECTIVE AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTITUBERCULAR AGENTS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; IMMUNOCOMPROMISED HOST; MALE; TRIMETHOPRIM, SULFAMETHOXAZOLE DRUG COMBINATION; TUBERCULOSIS;

EID: 84904968058     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu283     Document Type: Article

References (37)

1. World Health Organization. Global tuberculosis report 2013. Available at: http://www.who.int/tb/publications/global-report/en/. Accessed 1 April 2014.
2. Straetemans M, Bierrenbach AL, Nagelkerke N, Glaziou P, van der Werf MJ. The effect of tuberculosis on mortality in HIV positive people: a meta-analysis. PLoS One 2010; 5.
3. Abdool Karim SS, Naidoo K, Grobler A, et al. Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med 2011; 365: 1492-501.
4. Havlir DV, Kendall MA, Ive P, et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med 2011; 365: 1482-91.
5. Blanc FX, Sok T, Laureillard D, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med 2011; 365: 1471-81.
6. Török ME, Yen NTB, Chau TTH, et al. Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)-associated tuberculous meningitis. Clin Infect Dis 2011; 52: 1374-83.
7. Manosuthi W, Mankatitham W, Lueangniyomkul A, et al. Time to initiate antiretroviral therapy between 4 weeks and 12 weeks of tuberculosis treatment in HIV-infected patients: results from the TIME study. J Acquir Immune Defic Syndr 2012; 60: 377-83.
8. Cain KP, Anekthananon T, Burapat C, et al. Causes of death in HIV-infected persons who have tuberculosis, Thailand. Emerging Infect Dis 2009; 15: 258-64.
9. Cox JA, Lukande RL, Nelson AM, et al. An autopsy study describing causes of death and comparing clinico-pathological findings among hospitalized patients in Kampala, Uganda. PLoS One 2012; 7.
10. Greenberg AE, Lucas S, Tossou O, et al. Autopsy-proven causes of death in HIV-infected patients treated for tuberculosis in Abidjan, Côte d'Ivoire. AIDS 1995; 9: 1251-4.
11. van Griensven J, Thai S. Predictors of immune recovery and the association with late mortality while on antiretroviral treatment in Cambodia. Trans R Soc Trop Med Hyg 2011; 105: 694-703.
12. Swaminathan S, Padmapriyadarsini C, Venkatesan P, et al. Efficacy and safety of once-daily nevirapine-or efavirenz-based antiretroviral therapy in HIV-associated tuberculosis: a randomized clinical trial. Clin Infect Dis 2011; 53: 716-24.
13. National Center for HIV/AIDS Dermatology and STD Cambodia. National guidelines for the prophylaxis of opportunistic infections in people living with HIV/AIDS. Phnom Penh, Cambodia: Ministry of Health, 2003. Available at: http://www.nchads.org/Guideline/OI%20Guideline%20Booklet%20Kh.pdf. Accessed 1 April 2014.
14. Laureillard D, Marcy O, Madec Y, et al. Paradoxical tuberculosis- associated immune reconstitution inflammatory syndrome after early initiation of antiretroviral therapy in a randomized clinical trial. AIDS 2013; 27: 2577-86.
15. van Buuren S. Multiple imputation of discrete and continuous data by fully conditional specification. Stat Methods Med Res 2007; 16: 219-42.
16. Lawn SD, Harries AD, Anglaret X, Myer L, Wood R. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS 2008; 22: 1897-908.
17. Stringer JSA, Zulu I, Levy J, et al. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA 2006; 296: 782-93.
18. Anglaret X, Minga A, Gabillard D, et al. AIDS and non-AIDS morbidity and mortality across the spectrum of CD4 cell counts in HIV-infected adults before starting antiretroviral therapy in Cote d'Ivoire. Clin Infect Dis 2012; 54: 714-23.
19. Fregonese F, Collins IJ, Jourdain G, et al. Predictors of 5-year mortality in HIV-infected adults starting highly active antiretroviral therapy in Thailand. J Acquir Immune Defic Syndr 2012; 60: 91-8.
20. McGreevy J, Jean Juste MA, Severe P, et al. Outcomes of HIV-infected patients treated for recurrent tuberculosis with the standard retreatment regimen. Int J Tuberc Lung Dis 2012; 16: 841-5.
21. Nahid P, Jarlsberg LG, Rudoy I, et al. Factors associated with mortality in patients with drug-susceptible pulmonary tuberculosis. BMC Infect Dis 2011; 11: 1.
22. Català L, Orcau A, García de Olalla P, Millet JP, Rodríguez-Mondragón A, Caylà JA. Survival of a large cohort of HIV-infected tuberculosis patients in the era of highly active antiretroviral treatment. Int J Tuberc Lung Dis 2011; 15: 263-9, i.
23. Crump JA, Ramadhani HO, Morrissey AB, et al. Bacteremic disseminated tuberculosis in sub-Saharan Africa: a prospective cohort study. Clin Infect Dis 2012; 55: 242-50.
24. Boehme CC, Nabeta P, Hillemann D, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 2010; 363: 1005-15.
25. Tukvadze N, Kempker RR, Kalandadze I, et al. Use of a molecular diagnostic test in AFB smear positive tuberculosis suspects greatly reduces time to detection of multidrug resistant tuberculosis. PLoS One 2012; 7.
26. Feasey NA, Banada PP, Howson W, et al. Evaluation of Xpert MTB/RIF for detection of tuberculosis from blood samples of HIV-infected adults confirms Mycobacterium tuberculosis bacteremia as an indicator of poor prognosis. J Clin Microbiol 2013; 51: 2311-6.
27. Steingart KR, Jotblad S, Robsky K, et al. Higher-dose rifampin for the treatment of pulmonary tuberculosis: a systematic review. Int J Tuberc Lung Dis 2011; 15: 305-16.
28. Ruslami R, Ganiem AR, Dian S, et al. Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial. Lancet Infect Dis 2013; 13: 27-35.
29. Westreich DJ, Sanne I, Maskew M, et al. Tuberculosis treatment and risk of stavudine substitution in first-line antiretroviral therapy. Clin Infect Dis 2009; 48: 1617-23.
30. Phan V, Thai S, Choun K, Lynen L, van Griensven J. Incidence of treatment-limiting toxicity with stavudine-based antiretroviral therapy in Cambodia: a retrospective cohort study. PLoS One 2012; 7.
31. Osler M, Stead D, Rebe K, Meintjes G, Boulle A. Risk factors for and clinical characteristics of severe hyperlactataemia in patients receiving antiretroviral therapy: a case-control study. HIV Med 2010; 11: 121-9.
32. Manosuthi W, Prasithsirikul W, Chumpathat N, et al. Risk factors for mortality in symptomatic hyperlactatemia among HIV-infected patients receiving antiretroviral therapy in a resource-limited setting. Int J Infect Dis 2008; 12: 582-6.
33. Anglaret X, Chêne G, Attia A, et al. Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Côte d'Ivoire: a randomised trial. Cotrimo-CI Study Group. Lancet 1999; 353: 1463-8.
34. Lim P-L, Zhou J, Ditangco RA, et al. Failure to prescribe pneumocystis prophylaxis is associated with increased mortality, even in the cART era: results from the Treat Asia HIV observational database. J Int AIDS Soc 2012; 15: 1.
35. Walker AS, Ford D, Gilks CF, et al. Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort. Lancet 2010; 375: 1278-86.
36. Anglaret X, Eholie S. Co-trimoxazole, cART, and non-AIDS infectious diseases. Lancet 2010; 375: 1231-3.
37. Kumarasamy N, Vallabhaneni S, Cecelia AJ, et al. Safe discontinuation of primary pneumocystis prophylaxis in Southern Indian HIV-infected patients on highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2005; 40: 377-8.